NCT02930382

Brief Summary

We must implement 8 implantable cardioverter defibrillators (ICDs) to save a life in 3 years after myocardial infarction (MI) in primary prevention. Left ventricular ejection fraction (LVEF) is proposed as the one tool predicting sudden cardiac death after MI. Several studies have shown that impairment of spontaneous baroreflex sensitivity (BRS) after MI was predictor of sudden death.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
48

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started May 2016

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 26, 2016

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 26, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 26, 2016

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

October 10, 2016

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 12, 2016

Completed
Last Updated

August 8, 2018

Status Verified

August 1, 2018

Enrollment Period

Same day

First QC Date

October 10, 2016

Last Update Submit

August 6, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • spontaneous baroreflex sensitivity by the sequence method (mean slope)

    10 days

Study Arms (1)

BAROREFLEX

EXPERIMENTAL
Other: Baroreflex assessment

Interventions

BAROREFLEX

Eligibility Criteria

Age18 Years - 99 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients implanted with an implantable cardioverter defibrillator for primary prevention of of cardiac sudden death, ischaemic cardiomyopathy
  • Implantable cardioverter defibrillators implantation for at least 3 years
  • Age ≥ 18 years

You may not qualify if:

  • ventricular or atrial pacing ≥1%,
  • atrial fibrillation history
  • age under 18 years

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU DE Poitiers

Poitiers, 86021, France

Location

MeSH Terms

Conditions

Myocardial Infarction

Condition Hierarchy (Ancestors)

Myocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular DiseasesInfarctionIschemiaPathologic ProcessesPathological Conditions, Signs and SymptomsNecrosis

Study Design

Study Type
interventional
Phase
not applicable
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 10, 2016

First Posted

October 12, 2016

Study Start

May 26, 2016

Primary Completion

May 26, 2016

Study Completion

May 26, 2016

Last Updated

August 8, 2018

Record last verified: 2018-08

Locations